Stand Up To Cancer launched four new teams aimed at detecting and treating cancer in its earliest stages. Lung cancer expert Julie Brahmer, M.D., is the lead investigator for Johns Hopkins for lung cancer studies based at the Kimmel Cancer Center Thoracic Center of Excellence she directs. Victor Velculescu, M.D., Ph.D., an expert in the(...)
Research
A New Issue of Breast Matters
Posted by | Patient Stories, precision medicine, Prevention/Screening, Research, Survivorship, treatmentThe latest issue of Breast Matters is now out on newsstands, and we have it here for you in our brand new digital design. The new issue includes news on our GAITWAY Tumor board, a group of more than a dozen experts who match treatments to the unique genetic characteristics of patients’ tumors. It also(...)
What Every Lung Cancer Patient Needs to Know
Posted by | Research, treatmentIt’s lung cancer awareness month. “Many times patients come to us and they’ve been told they don’t have hope. We always have hope,” says Peggy Lang, nurse practitioner and coordinator of the Johns Hopkins Kimmel Cancer Center Thoracic Multidisciplinary Clinic and Lung Cancer Screening Program. In this video, she explains what every patient facing a(...)
Stand Up To Cancer Catalyst® Launches 10 Clinical Trial Projects
Posted by | ResearchJohns Hopkins Kimmel Cancer Center researchers and clinicians are among the leaders of one of the 10 Stand Up To Cancer (SU2C) Catalyst® clinical trial projects. Researchers from more than 30 institutions are collaborating across academic and corporate borders on clinical trials aimed at understanding why treatments are effective—across a variety of cancers—in a program(...)
Epigenetic Drugs Reset Genes in Breast, Colon Cancers But Didn’t Shrink Tumors
Posted by | Research, treatment--Two clinical trials suggest promise for using these medications in combination with other cancer therapies Two clinical trials using combinations of drugs meant to change cancer epigentics —or the way tumors express genes — failed at shrinking colon and breast tumors. However, these trials open the door for others currently in the works to combine(...)
How common is prostate cancer?
Posted by | ResearchProstate cancer is extremely common in the U.S. “It’s the most common life-threatening cancer in men, responsible for 26,000 deaths per year,” says William G. Nelson, M.D., Ph.D., director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. But there are a lot of prostate cancers that are not life-threatening, he says. “In autopsies(...)
Stefanie Joho describes how she participated in a landmark clinical trial of immunotherapy
Posted by | ResearchWhen doctors told Stefanie Joho that they had no options left, her sister scoured the internet to find "something" that could offer hope. She found a clinical trial at Johns Hopkins that looked promising, and little did Stefanie know that it would transform her life and become FDA approved. Listen to Stefanie tell her story:
Top Maryland scientists discuss research on tracking and treating cancer
Posted by | ResearchAt the annual Research Matters conference yesterday, top scientists from the Johns Hopkins Kimmel Cancer Center and University of Maryland Greenebaum Cancer Center discussed research using advanced imaging methods to develop better ways pinpoint and track cancer cells — down to the microscopic level — and precisely target each cell with anti-cancer drugs. Experts also delivered presentations(...)
Johns Hopkins Student Wins Top Prize For Research on Lethal Brain Tumors in Children
Posted by | Childhood Cancer, ResearchJohns Hopkins undergraduate student Sabrina Wang won first place in a competition among 125 students for her research on a lethal type of pediatric brain tumor called atypical teratoid/rhabdoid tumors (AT/RT), the most common brain tumor type in infants. The award was presented at the AACR 2017 annual meeting in Washington, D.C., on April 2.(...)
Top Questions Ahead for Cancer Immunotherapy
Posted by | ResearchA decade ago, Suzanne Topalian, M.D., led a team of researchers who made an astonishing contribution to how cancer is fought. Many cancers can “put the brakes” on the body’s immune cells — cells that would normally storm into a tumor and destroy it. Topalian, director of the Melanoma Program at the Johns Hopkins Kimmel(...)